Evidence map›Paper›PMID 31655493›Full record

ArticleBritish journal of pharmacology2020

Mu and delta opioid receptors play opposite nociceptive and behavioural roles on nerve-injured mice.

Miriam Martínez-Navarro, David Cabañero, Agnieszka Wawrzczak-Bargiela, Anne Robe, Claire Gavériaux-Ruff, Brigitte L Kieffer, Ryszard Przewlocki, Josep E Baños, Rafael Maldonado

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Miriam Martínez-NavarroLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0003-3216-0909
David CabañeroLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Agnieszka Wawrzczak-BargielaDepartment of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Anne RobeDepartment of Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, Strasbourg, France.
Claire Gavériaux-RuffDepartment of Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, Strasbourg, France.
Brigitte L KiefferDepartment of Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, Strasbourg, France.
Ryszard PrzewlockiDepartment of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.ORCID 0000-0003-4606-1629
Josep E BañosLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Rafael MaldonadoLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-4359-8773
Universitat Pompeu Fabra · ESCentre National de la Recherche Scientifique · FRMaj Institute of Pharmacology · PL

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-669Agència de Gestió d'Ajuts Universitaris i de Recerca #ICREA Acadèmia-2015Catalan Government AGAUR 2017-SGR-669Catalan Government AGAUR ICREA Acadèmia-2015European Commission FP7 HEALTH-F2-2013-602891FP7 Health HEALTH-F2-2013-602891Instituto de Salud Carlos III RETICS/RTA #RD16/0017Ministerio de Ciencia e Innovación SAF2017-84060-R-AEI/FEDER-UEMinisterio de Educación, Cultura y Deporte FPU13/06575Ministerstwo Nauki i Szkolnictwa Wyższego 3070/7.PR/2014/2Polish Ministry of Science and Higher Education 3070/7.PR/2014/2Spanish Ministry of Science, Innovation and Universities SAF2017-84060-R-AEI/FEDER-UE
6 · The paper itself

Abstract

background and purposeMu and delta opioid receptors(MOP, DOP) contribution to the manifestations of pathological pain is not understood. We used genetic approaches to investigate the opioid mechanisms modulating neuropathic pain and its comorbid manifestations. EXPERIMENTAL APPROACH: We generated conditional knockout mice with MOP or DOP deletion in sensoryNav1.8-positive neurons (Nav1.8), in GABAergic forebrain neurons (DLX5/6) orconstitutively (CMV). Mutant mice and wild-type littermates were subjected topartial sciatic nerve ligation (PSNL) or sham surgery and their nociception wascompared. Anxiety-, depressivelike behaviour and cognitive performance were also measured. Opioid receptor mRNA expression, microgliosis and astrocytosis were assessed in the dorsalroot ganglia (DRG) and/or the spinal cord (SC). KEY

resultsConstitutive CMV-MOP knockouts after PSNL displayed reduced mechanical allodynia and enhanced heat hyperalgesia. This phenotype was accompanied by increased DOP expression in DRG and SC, and reduced microgliosis and astrocytosis in deep dorsal horn laminae. Conditional MOP knockouts and control mice developed similar hypersensitivity after PSNL, except for anenhanced heat hyperalgesia by DLX5/6-MOP male mice. Neuropathic pain-induced anxiety was aggravated in CMV-MOP and DLX5/6-MOP knockouts. Nerve-injured CMV-DOP mice showed increased mechanical allodynia, whereas Nav1.8-DOP and DLX5/8-DOP mice had partial nociceptive enhancement. CMV-DOP and DLX5/6-DOP mutants showed increased depressive-like behaviour after PSNL. CONCLUSIONS AND IMPLICATIONS: MOP activity after nerve injury increased anxiety-like responses involving forebrain GABAergic neurons and enhanced mechanical pain sensitivity along with repression of DOP expression and spinal cord gliosis. In contrast, DOP shows a protective function limiting nociceptive and affective manifestations of neuropathic pain.

Indexed as

NociceptionReceptors, Opioid, deltaAnimalsHyperalgesiaMaleMiceMice, Neurologic MutantsReceptors, OpioidReceptors, Opioid, muReceptors, OpioidReceptors, Opioid, deltaReceptors, Opioid, mu

Identifiers

PMID31655493
PMCPMC7042108
OpenAlexW2981882335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.